Sustaining Remission of Psychotic Depression

Phase 4

Completed

• Conditions: Psychotic Depression
• Interventions: Drug: Sertraline + Olanzapine; Drug: Sertraline + Placebo

• Registration Number: NCT01427608
• Lead Sponsor: Weill Medical College of Cornell University

Brief Summary

The acute phase of this study will monitor the response to a combination of an atypical antipsychotic medication olanzapine with an antidepressant medication sertraline in the acute treatment of the disorder. It is predicted that this combination will improve symptoms of psychotic depression and be associated metabolic side effects. Factors that moderate tolerability will be monitored. Improvement in symptoms could take between 4 and 12 weeks, followed by a period of 8 weeks during which participants will continue to take the same medications to stabilize the remission from symptoms of psychotic depression.

The maintenance phase will be a randomized, double-blind, placebo-controlled study of olanzapine for a period of up to 36 weeks to test whether continuing this combination decreases the risk of relapse and whether discontinuing the combination leads to improvement in metabolic measures. Subjects who complete the acute phase will be asked to consent separately to the randomized maintenance phase.

Detailed Description

The original STOP-PD study established that the combination of olanzapine and sertraline was significantly better than olanzapine alone in achieving remission of psychotic depression. This STOP-PD-II Sustaining Remission study aims to assess the long-term tolerability of taking this combination of medications and their efficacy at preventing a relapse of the symptoms. The acute phase of the study will monitor the efficacy and tolerability of the olanzapine and sertraline combination, including investigation of weight and metabolic variables, age effects on treatment response and tolerability, and the association of genetic polymorphisms to response or relapse. When subjects are stabilized on these medications for a period of 8 weeks they will be invited to participate in the randomized phase of the research: the olanzapine will be placebo-controlled, meaning half of the subjects will continue to take the olanzapine/sertraline combination and half will take a sertraline/placebo combination, for a period of 36 weeks. Symptoms and side effects will be monitored regularly throughout this phase. Randomization will be stratified on a 1:1 basis by age 60 and above.

Study Timeline

• Study First Submitted: 2011-08-30
• Study First Submitted QC: 2011-08-31
• Study First Posted: 2011-09-01
• Study Start: 2011-10
• Primary Completion: 2017-11-30
• Study Completion: 2017-11-30
• Results First Submitted: 2018-12-17
• Status Verified: 2019-02
• Results First Submitted QC: 2019-02-13
• Last Update Submitted: 2019-02-13
• Results First Posted: 2019-03-05
• Last Update Posted: 2019-03-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 269

Inclusion Criteria

1. Aged 18-85 years, inclusive
2. Diagnosis: Diagnostic Statistical Manual-IV Trade Revision (DSM IV-TR) non-bipolar major depression with psychotic features established by both clinical interview with research psychiatrist and administration of SCID-IV.
3. Score >2 on Schedule for Affective Disorders (SADS) delusion severity item
4. Score >1 on any of the three conviction items of the Delusion Assessment Scale (DAS) (does not alter belief in response to reality testing)
5. 17-item HAM-D score of >20

Read More

Exclusion Criteria

1. Current or lifetime DSM-IV-TR history of schizophrenia or other psychotic disorders or meeting current criteria for brief psychotic disorder, body dysmorphic disorder or obsessive-compulsive disorder
2. Current or lifetime DSM-IV-TR bipolar affective disorder
3. History of DSM-IV-TR defined alcohol or substance abuse or dependence within the past three months
4. Dementia or clinically significant cognitive impairment prior to index episode of depression, and/or a mean score >3 on 26-item caregiver assessment
5. Type 1 diabetes mellitus (defined as insulin-dependent diabetes mellitus with onset before age 35, and/or diabetes mellitus complicated by prior documented episode of ketoacidosis
6. Acute or unstable medical illness within the past 3 months; current abnormal serum free T4; current abnormally low vitamin B4 or folic acid level; medical conditions and/or medications for which psychotic or depressive symptoms can be a direct manifestation; neurological disease associated with extrapyramidal signs and symptoms; epilepsy, if the person has had one or more grand mal seizures within the past 12 months.
7. The need for treatment with any psychotropic medication other than sertraline, olanzapine or lorazepam; or with an anticonvulsant medication with mood-stabilizing properties.
8. Current pregnancy or plan to become pregnant during the course of the study; breast feeding in women with infants.
9. A documented history of being unable to tolerate olanzapine or sertraline including significant bradycardia (heart rate of <50 bpm), and serum sodium level of 129mmol/L or below.
10. History of non-response of the index episode of psychotic depression to at least a 6-week trial of at least 150mg/day sertraline combined with 15mg/day olanzapine
11. Patients showing ongoing improvement in current episode of psychotic depression with treatment other than sertraline or olanzapine
12. Patients who are in immediate need of electroconvulsive therapy (ECT) (imminent risk of suicide, refusing to eat, catatonic)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sertraline + Olanzapine	Sertraline + Olanzapine	Randomized to continue with sertraline and olanzapine under double-blind conditions.
Sertraline + Placebo	Sertraline + Placebo	Randomized to continue with sertraline and substitute placebo for olanzapine under double-blind conditions.

Primary Outcome Measures

Name	Time	Method
Number of Subjects at Risk of Relapse During the Randomized Phase.	From entry into randomized phase (baseline) and 36 weeks or earlier relapse	Relapse criteria include at least one of the following: 1)Structured Clinical Interview for Diagnostic Statistical Manual #4 Trade Revision (DSM-IV-TR) Axis 1 Disorders (SCID) symptoms of major depression maintained over two weeks 2)17-item Hamilton Depression Rating Scale score of \>17 maintained for more than one week + a mean increase of 5 points from entry into randomized phase 3)Re-emergence of psychosis for more than one week, with a SADS (Schedule for Affective Disorders and Schizophrenia) score of \>2 on delusion or hallucination severity items 4)Significant clinical worsening defined as either emergence of high-risk of suicide, and/or development of mania for greater than one week, and/or psychiatric hospitalization.

Secondary Outcome Measures

Name	Time	Method
Changes in Metabolic Measures: Weight	From entry into randomized phase (baseline) and 36 weeks	Change in weight from entry into randomized phase (baseline) and 36 weeks.
Changes in Metabolic Measure: Cholesterol	From entry into randomized phase (baseline) and 36 weeks	Change in cholesterol from entry into randomized phase (baseline) and 36 weeks.
Changes in Metabolic Measures: Triglycerides	From entry into randomized phase (baseline) and 36 weeks	Change in triglycerides from entry into randomized phase (baseline) and 36 weeks.

Trial Locations

Locations (4)

Anthony Rothschild, MD; 🇺🇸 Worcester, Massachusetts, United States

George Alexopoulos, MD; 🇺🇸 White Plains, New York, United States

Ellen Whyte, MD; 🇺🇸 Pittsburgh, Pennsylvania, United States

Alastair Flint, MD; 🇨🇦 Toronto, Canada